晚期卵巢癌預(yù)后普遍不佳，當(dāng)前的治療策略效果有限。貝伐珠單抗通過(guò)抑制血管內(nèi)皮生長(zhǎng)因子A (VEGF-A)活性，有效阻斷腫瘤新生血管形成，從而抑制腫瘤的生長(zhǎng)。多項(xiàng)研究結(jié)果顯示，貝伐珠單抗能顯著改善卵巢癌患者的預(yù)后，并且被國(guó)內(nèi)外多個(gè)臨床指南推薦用于晚期卵巢癌的治療。然而，貝伐珠單抗在臨床應(yīng)用中尚未得到廣泛接受和規(guī)范使用，尤其在應(yīng)用范圍、聯(lián)合用藥策略、耐藥性以及藥物不良反應(yīng)等方面存在爭(zhēng)議。系統(tǒng)梳理貝伐珠單抗在卵巢癌治療中的作用機(jī)制、用藥策略與療效、安全性以及耐藥情況，對(duì)于評(píng)價(jià)其臨床治療價(jià)值、探索科學(xué)用藥具有重要意義。

The prognosis of advanced ovarian cancer（AOC） is generally poor, and the current treatment strategies have limited effectiveness. Bevacizumab effectively inhibits the activity of vascular endothelial growth factor A（VEGF-A） by blocking the formation of new blood vessels in tumors, thereby suppressing tumor growth. Multiple studies have shown that this drug can significantly improve the AOC patients and has been recommended by multiple clinical guidelines for the treatment of AOC. However, Bevacizumab has not yet been widely accepted and standardized in clinical applications, and there are controversies regarding its application scope, combination therapy strategies, drug resistance, and adverse drug reactions. Systematically reviewing the mechanism of action, medication strategies and efficacy, safety, and drug resistance of bevacizumab in the treatment of AOC is of great significance for evaluating its clinical therapeutic value and exploring scientific drug use.

R979.1

安徽省高校自然科學(xué)研究重大項(xiàng)目(KJ2019ZD73); 安徽省高校優(yōu)秀青年骨干人才項(xiàng)目(gxgwfx2019068)